DVA

NEUTRAL

$151.85 Live

DaVita Inc. · NYSE

Target $151.71 (-0.1%)

$101.0 52W Range $159.42

DVA DaVita Inc. - Fundamental Analysis

NEUTRAL

Console Chart News

DVA Stock | Fundamental Analysis & Investment Insights

NYSE • Healthcare • Medical Care Facilities

Current Price Live

$151.85

Analyst Target

$151.71

-0.1% Downside

52W High

$159.42

52W Low

$101.0

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 26, 2026

Market cap

$10.01B

P/E

15.97

ROE

64.8%

Profit margin

5.5%

Debt/Equity

11.11

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

DaVita Inc. presents a dichotomy between attractive valuation and precarious financial leverage, anchored by a stable but mediocre Piotroski F-Score of 4/9. While the stock trades at a compelling Forward P/E of 9.26 and a PEG ratio of 0.56, suggesting significant undervaluation relative to growth, this is offset by an extreme Debt/Equity ratio of 11.11 and negative book value. Bearish insider sentiment, characterized by a $199.94M sale, and a weak technical trend (10/100) further temper the bullish case. The stock is currently trading very close to its analyst target price and intrinsic value, leaving limited immediate upside.

Key Strengths

Highly attractive valuation with a Forward P/E of 9.26

Strong growth efficiency indicated by a PEG ratio of 0.56

Consistent historical track record of earnings beats over 25 quarters

Steady top-line revenue growth of 9.90% YoY

High ROE of 64.85% (though amplified by leverage)

Key Risks

Extreme financial leverage with a Debt/Equity ratio of 11.11

Negative Price/Book ratio (-15.99) indicating negative shareholder equity

Strongly bearish insider activity with significant recent selling

Negative Q/Q earnings growth of -9.70%

Weak technical momentum (10/100 trend score)

AI Fair Value Estimate

Based on comprehensive analysis

$155.5

+2.4% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Moderate

Value

Future

Past

Health

Dividend

AI Verdict

Value Trap Risk

Key drivers: Low valuation multiples, Extreme debt levels, Bearish insider/technical signals

Confidence

80%

Value

85/100

P/E 15.97, Forward P/E 9.26, PEG 0.56

Positives

Low Forward P/E
Very low PEG ratio
Trading slightly below intrinsic value

Watchpoints

Negative book value

Future

60/100

YoY Revenue Growth 9.90%, Q/Q Earnings Growth -9.70%

Positives

Consistent YoY revenue growth

Watchpoints

Recent Q/Q earnings contraction
Bearish technical trend

Past

75/100

25 quarters of earnings data showing frequent beats

Positives

Long-term earnings beat consistency
Positive 3Y and 5Y price performance

Watchpoints

Recent volatility in quarterly surprises

Health

30/100

Debt/Equity 11.11, Piotroski 4/9

Positives

Current ratio above 1.0

Watchpoints

Extreme Debt/Equity ratio
Piotroski F-Score of 4/9 (Stable but not strong)
Negative equity

Dividend

0/100

Dividend Yield N/A, Payout 0%

Positives

No standout positives identified.

Watchpoints

No dividend payments

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$151.85

Analyst Target

$151.71

Upside/Downside

-0.1%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for DVA and closest competitors.

Updated 2026-04-24

Company	5Y	3Y	1Y	6M	1M	1W
DVA DaVita Inc. Primary	+34.0%	+73.9%	+8.8%	+17.5%	-2.1%	+2.7%
EHC Encompass Health Corporation Peer	+54.8%	+64.6%	+1.2%	-18.8%	+3.4%	-4.2%
TEM Tempus AI, Inc. Peer	+41.1%	+41.1%	+38.6%	-38.6%	+20.9%	+23.5%
BIO-B Bio-Rad Laboratories, Inc. Peer	-47.0%	-22.7%	-10.4%	+26.6%	+0.7%	+0.7%
TECH Bio-Techne Corporation Peer	-41.6%	-26.4%	+28.2%	-2.9%	+17.7%	+5.3%

DVA

DaVita Inc.

Primary

+34.0%

+73.9%

+8.8%

+17.5%

-2.1%

+2.7%

EHC

Encompass Health Corporation

Peer

+54.8%

+64.6%

+1.2%

-18.8%

+3.4%

-4.2%

TEM

Tempus AI, Inc.

Peer

+41.1%

+38.6%

-38.6%

+20.9%

+23.5%

BIO

Bio-Rad Laboratories, Inc.

Peer

-47.0%

-22.7%

-10.4%

+26.6%

+0.7%

TEC

Bio-Techne Corporation

Peer

-41.6%

-26.4%

+28.2%

-2.9%

+17.7%

+5.3%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

15.97

9.26

0.56

-15.99

0.73

1.77

8.77

$10.01B

Profitability

Profit margins and return metrics

Profit Margin 5.47%

Operating Margin 15.23%

Gross Margin 32.26%

ROE 64.85%

ROA 7.32%

Growth

Revenue and earnings growth rates

Revenue Growth +9.9%

Earnings Growth +6.5%

Q/Q Revenue Growth +9.87%

Q/Q Earnings Growth -9.7%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

11.11

High debt

Current Ratio

1.29

Good

Quick Ratio

1.17

Good

Cash/Share

$10.49

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$3.6B

Gross Margin

33.4%

Op. Margin

15.2%

Net Margin

6.5%

Total Assets

$17.5B

Liabilities

$16.3B

Equity

$-0.7B

Debt/Equity

-25.07x

Operating CF

$0.5B

CapEx

$-0.1B

Free Cash Flow

$0.4B

FCF Yield

73%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-05

$N/A

2026-02-02

$3.4

+6.5% surprise

2025-10-29

$2.51

-20.9% surprise

2025-08-05

$2.95

+7.3% surprise

Healthcare Sector Comparison

Comparing DVA against 548 companies in the Healthcare sector (30 bullish, 163 neutral, 355 bearish)

P/E Ratio

15.97

This Stock

77.48

Sector Avg

-79.4% (Discount)

Return on Equity (ROE)

64.85%

This Stock

-89.9%

Sector Avg

-172.1% (Below Avg)

Profit Margin

5.47%

This Stock

-16.4%

Sector Avg

-133.4% (Weaker)

Debt to Equity

11.11

This Stock

2.71

Sector Avg

+310.0% (Higher)

Revenue Growth

9.9%

This Stock

126.74%

Sector Avg

-92.2% (Slower)

Current Ratio

1.29

This Stock

4.53

Sector Avg

-71.5% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
DVA DaVita Inc.	NEUTRAL	$10.01B	15.97	64.8%	5.5%	$151.85
EHC Encompass Health Corporation	BULLISH	$10.14B	18.37	24.8%	9.5%	$101.98	Compare
TEM Tempus AI, Inc.	BEARISH	$10.19B	-	-89.5%	-19.3%	$56.78	Compare
BIO-B Bio-Rad Laboratories, Inc.	BEARISH	$9.79B	-	-9.5%	-26.4%	$312.75	Compare
TECH Bio-Techne Corporation	NEUTRAL	$9.48B	114.3	4.0%	6.7%	$60.58	Compare

DVA DaVita Inc.

NEUTRAL

Mkt Cap

$10.0B

P/E

16.0

ROE

64.8%

Price

$151.85

Compare with DVA

Compare with DVA

Compare with DVA

TECH Bio-Techne Corporation

Compare with DVA

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-03-13	PULLIN DENNIS W	Director	Stock Award	332	-
2026-03-13	SCHOPPERT WENDY LEE	Director	Stock Award	332	-
2026-03-13	MAUGHAN DAVID PAUL	Officer	Stock Award	5,308	-
2026-03-13	RODRIGUEZ JAVIER J	Chief Executive Officer	Stock Award	20,900	-
2026-03-13	YALE PHYLLIS R	Director	Stock Award	332	-
2026-03-13	SCHECHTER ADAM H	Director	Stock Award	332	-
2026-03-13	ARWAY PAMELA M.	Director	Stock Award	332	-
2026-03-13	BERRY CHRISTOPHER MICHAEL	Officer	Stock Award	3,649	-
2026-03-13	WATERS KATHLEEN ALYCE	Officer	Stock Award	3,185	-
2026-03-13	HOLLAR JASON M	Director	Stock Award	332	-
2026-03-13	HEARTY JAMES O	Officer	Stock Award	1,128	-
2026-03-13	MOORE GREGORY J	Director	Stock Award	332	-
2026-03-13	DESOER BARBARA J	Director	Stock Award	332	-
2026-03-13	ACKERMAN JOEL	Chief Financial Officer	Stock Award	5,706	-
2026-03-10	WATERS KATHLEEN ALYCE	Officer	Stock Award	56,159	-

PULLIN DENNIS W

Director

Stock Award

2026-03-13

332 shares

SCHOPPERT WENDY LEE

Director

Stock Award

2026-03-13

332 shares

MAUGHAN DAVID PAUL

Officer

Stock Award

2026-03-13

5,308 shares

RODRIGUEZ JAVIER J

Chief Executive Officer

Stock Award

2026-03-13

20,900 shares

YALE PHYLLIS R

Director

Stock Award

2026-03-13

332 shares

SCHECHTER ADAM H

Director

Stock Award

2026-03-13

332 shares

ARWAY PAMELA M.

Director

Stock Award

2026-03-13

332 shares

BERRY CHRISTOPHER MICHAEL

Officer

Stock Award

2026-03-13

3,649 shares

WATERS KATHLEEN ALYCE

Officer

Stock Award

2026-03-13

3,185 shares

HOLLAR JASON M

Director

Stock Award

2026-03-13

332 shares

HEARTY JAMES O

Officer

Stock Award

2026-03-13

1,128 shares

MOORE GREGORY J

Director

Stock Award

2026-03-13

332 shares

DESOER BARBARA J

Director

Stock Award

2026-03-13

332 shares

ACKERMAN JOEL

Chief Financial Officer

Stock Award

2026-03-13

5,706 shares

WATERS KATHLEEN ALYCE

Officer

Stock Award

2026-03-10

56,159 shares

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

DEF 14A

2026-04-22

DVA filed a Definitive Proxy Statement on April 22, 2026, providing shareholders with necessary information and voting materials for an upcoming meeting.

10-K

2026-02-11

DVA filed its 10-K annual report on February 11, 2026. The provided excerpts identify the inclusion of Business, Risk Factors, and Management's Discussion and Analysis sections, although specific financial highlights and risk details were not provided.

8-K

2026-02-02

DaVita Inc. likely filed this 8-K to announce its fourth-quarter and full-year 2025 financial results.

8-K

CURRENT REPORT

2025-11-25

10-Q

2025-10-29

DVA submitted its 10-Q filing on October 29, 2025. While the document includes a section for Risk Factors under Item 1A, specific financial highlights and detailed risk disclosures were not provided in the available excerpt.

8-K

2025-10-29

DaVita Inc. filed a current report on October 29, 2025, likely to announce its third-quarter financial results.

8-K

2025-08-20

DaVita Inc. filed an 8-K on August 20, 2025, likely to announce its second-quarter financial results.

10-Q

2025-08-05

DVA filed its 10-Q on August 5, 2025. The provided excerpt identifies the existence of a Risk Factors section, although specific financial highlights and detailed risk descriptions were not included in the available text.

8-K

2025-08-05

DaVita Inc. likely filed this 8-K to announce its second-quarter financial results.

8-K

2025-07-17

8-K

2025-06-09

8-K

CURRENT REPORT

2025-05-23

8-K

CURRENT REPORT

2025-05-20

8-K

CURRENT REPORT

2025-05-20

10-Q

2025-05-12

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

NONE

7 analysts

UBS

2026-02-04

Maintains

Buy Buy

Barclays

2026-02-03

Maintains

Equal-Weight Equal-Weight

TD Cowen

2025-11-03

Maintains

Hold Hold

Barclays

2025-10-30

Maintains

Equal-Weight Equal-Weight

Past News Coverage

Recent headlines mentioning DVA from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

DVA

DVA DaVita Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!